A large number of pharmaceutical companies have unsatisfactory cross-border effects. How to solve the dilemma?

With the continuous deepening of policies such as consistency evaluation and volume procurement, in recent years, many domestic pharmaceutical companies, especially established pharmaceutical companies, have begun to see a decline in their income
.
It is worth noting that, in order to save the main business income and transform and upgrade, currently pharmaceutical companies have begun to choose to cross-border and extend their business scope
.
Pharmaceutical companies have begun to cross-border gold mining.
Recently, there are reports that North China Pharmaceutical's "Zhenyinzi" tea brand will begin to attract investment
.
It is understood that the "Zhenyinzi" brand belongs to Hebei Huawei Health Industry Co.
, Ltd.
, and North China Pharmaceutical holds 51% of the company's equity
.
On August 14 this year, Zhen Yinzi's first store opened in Shijiazhuang, Hebei
.
Why did that pharmaceutical manufacturing company start buying milk tea? Analysis believes that the reason why North China Pharmaceutical sells milk tea is that, on the one hand, its own performance is not strong
.
It is understood that Huabei Pharmaceutical is mainly engaged in the R&D, production and sales of pharmaceutical products
.
However, in the context of the continuous expansion of the pharmaceutical market in recent years, from 2017 to 2020, the net profit of North China Pharmaceuticals after non-deduction has been continuously reduced, respectively 22 million yuan, 22 million yuan, 116 million yuan and -62 million yuan.
; The growth rates over the same period were 142.
85%, 2.
45%, 483.
17% and -153.
96%
.
On the other hand, the development of ready-made tea beverage industries such as milk tea is relatively hot
.
According to statistics, the scale of China's current tea market (calculated by retail sales) will reach 113.
6 billion yuan in 2020, and it is expected to reach 340 billion yuan by 2025, with a compound annual growth rate of 24.
5%
.
The total number of stores is 334,000, which is expected to reach 390,000 in 2021, a year-on-year increase of 16.
8%
.
At present, in addition to North China Medicine, there are actually a large number of pharmaceutical companies in tea, daily necessities and other industries that are entering the market across the border
.
For example, at the beginning of November this year, Zhang Zhongjing Pharmacy launched the "Healthy Coffee"; and last year, Zhang Zhongjing Pharmacy also launched the "Zhongjing Life Museum" centering on "the same medicine and food, healthy health preservation"
.
In addition, pharmaceutical companies such as Tongrentang, Ma Yinglong, and China Resources Sanjiu have also been deployed in the beauty and cosmetics field.

.
Among them, on July 30, Renhe Pharmaceutical also announced the acquisition of 7 cosmetics companies, with a total transaction volume of 720 million yuan
.
It is worth mentioning that this year Yixintang also "hand in hand" with the Yunnan Sports Lottery Management Center, and has crossed over to the lottery business
.
How to solve the cross-border dilemma of pharmaceutical companies? On the whole, the cross-border business categories of domestic pharmaceutical companies are already very rich, covering many fields from daily chemicals to health care to maternal and child pregnancy and birth, and has formed a novel landscape
.
However, it should be noted that some analysts also pointed out that most of the pharmaceutical companies that choose to cross-border have yet to find a precise positioning, and blindly exert their efforts on pseudo-demand and imaginary demand
.
As a result, so far, there are few successful cross-border operations in the pharmaceutical industry
.
In the context of unsatisfactory cross-border effects, how should these established pharmaceutical companies achieve transformation and upgrading and improve their performance? In this regard, industry insiders put forward three suggestions, one is to solve the problem fundamentally, that is, to increase investment in research and development
.
In fact, the main problem of transformation is to solve the problems of internal management confusion, rigid management thinking, and lack of innovation
.
Therefore, strengthening the company's internal governance and improving competitiveness are the primary issues that need to be resolved urgently
.
Only after solving the problems that caused internal management chaos, can we increase investment in product research and development and carry out useful business model innovations
.
And if there is greater pressure on innovation, you can start with heavy generic drugs to reduce input costs and increase the speed of innovation
.
The second is based on its own cost advantages to achieve economies of scale
.
On the whole, pharmaceutical companies are fundamental to good medicine, and good medicine-related product development and services are the way out
.
From the current point of view, most of the successful cross-border pharmaceutical companies are large brands and large companies, while other companies have more time to "accompany" and have less success
.
Therefore, the matter of cross-border operation requires long-term consideration and intensive cultivation, and the main business should be done first
.
Third, if you really want to rely on cross-border transformation, then you must inherit the genes of pharmaceutical companies and smash product quality, and serve consumers with sufficient sincerity
.
Compared with the form of promoting cooperative joint models, the company's self-built production lines and the daily necessities and foods developed through independent research and development may be more empowering for the healthy development of pharmaceutical companies
.